These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 9606778)

  • 1. Urodynamic predictors of upper tract deterioration in children with myelodysplasia.
    Shoukry MS; El Salmy S; Aly GA; Mokhless I
    Scand J Urol Nephrol; 1998 Apr; 32(2):94-7. PubMed ID: 9606778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ultrasonographic measurement of bladder wall thickness as a risk factor for upper urinary tract deterioration in children with myelodysplasia.
    Tanaka H; Matsuda M; Moriya K; Mitsui T; Kitta T; Nonomura K
    J Urol; 2008 Jul; 180(1):312-6; discussion 316. PubMed ID: 18499168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An objective score to predict upper tract deterioration in myelodysplasia.
    Galloway NT; Mekras JA; Helms M; Webster GD
    J Urol; 1991 Mar; 145(3):535-7. PubMed ID: 1997704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An analysis of risk factors for upper urinary tract deterioration in patients with myelodysplasia.
    Seki N; Akazawa K; Senoh K; Kubo S; Tsunoda T; Kimoto Y; Naito S
    BJU Int; 1999 Oct; 84(6):679-82. PubMed ID: 10510115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Urological complications in children with myelodysplasia].
    Nikolaev VV; Braev AT
    Urologiia; 2000; (2):40-2. PubMed ID: 11186729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relevance of urethral resistance in children with myelodysplasia: its impact on upper urinary tract deterioration and the outcome of conservative management.
    Tanaka H; Kakizaki H; Kobayashi S; Shibata T; Ameda K; Koyanagi T
    J Urol; 1999 Mar; 161(3):929-32. PubMed ID: 10022727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urinary NGF, TGF-β1, TIMP-2 and bladder wall thickness predict neurourological findings in children with myelodysplasia.
    Şekerci ÇA; Işbilen B; Işman F; Akbal C; Şimşek F; Tarcan T
    J Urol; 2014 Jan; 191(1):199-205. PubMed ID: 23973519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Value of Urinary Brain-Derived Neurotrophic Factor Levels on the Assessment of Botulinum Toxin Type A Treatment for Neurogenic Detrusor Overactivity in Children with Myelodysplasia.
    Sekerci CA; Tanidir Y; Toprak T; Basok BI; Isman F; Simsek F; Akbal C; Tarcan T
    J Urol; 2019 Jan; 201(1):174-180. PubMed ID: 30577408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The urodynamic profile of myelodysplasia in childhood with spinal closure during gestation.
    Holzbeierlein J; Pope JC IV; Adams MC; Bruner J; Tulipan N; Brock JW
    J Urol; 2000 Oct; 164(4):1336-9. PubMed ID: 10992409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between the findings of a clinical neurological examination and the urodynamic dysfunction in children with myelodysplasia.
    Wyndaele JJ; De Sy WA
    J Urol; 1985 Apr; 133(4):638-40. PubMed ID: 3981715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urethral dilation as treatment for neurogenic bladder.
    Kiddoo DA; Canning DA; Snyder HM; Carr MC
    J Urol; 2006 Oct; 176(4 Pt 2):1831-3; discussion 1834. PubMed ID: 16945663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of children with myelodysplasia: urological alternatives.
    Klose AG; Sackett CK; Mesrobian HG
    J Urol; 1990 Dec; 144(6):1446-9. PubMed ID: 2231940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prophylactic value of clean intermittent catheterization and anticholinergic medication in newborns and infants with myelodysplasia at risk of developing urinary tract deterioration.
    Kasabian NG; Bauer SB; Dyro FM; Colodny AH; Mandell J; Retik AB
    Am J Dis Child; 1992 Jul; 146(7):840-3. PubMed ID: 1496955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Postpubertal urodynamic and upper urinary tract changes in children with conservatively treated myelomeningocele.
    Almodhen F; Capolicchio JP; Jednak R; El Sherbiny M
    J Urol; 2007 Oct; 178(4 Pt 1):1479-82. PubMed ID: 17706702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal deterioration in myelodysplastic children: urodynamic evaluation and clinical correlates.
    Kurzrock EA; Polse S
    J Urol; 1998 May; 159(5):1657-61. PubMed ID: 9554387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The value of urodynamic testing in the management of neonates with myelodysplasia: a prospective study.
    Sidi AA; Dykstra DD; Gonzalez R
    J Urol; 1986 Jan; 135(1):90-3. PubMed ID: 3941475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relevance of detrusor hyperreflexia, vesical compliance and urethral pressure to the occurrence of vesicoureteral reflux in myelodysplastic patients.
    Kobayashi S; Shinno Y; Kakizaki H; Matsumura K; Koyanagi T
    J Urol; 1992 Feb; 147(2):413-5. PubMed ID: 1732605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does surgical release of secondary spinal cord tethering improve the prognosis of neurogenic bladder in children with myelomeningocele?
    Tarcan T; Onol FF; Ilker Y; Simsek F; Ozek M
    J Urol; 2006 Oct; 176(4 Pt 1):1601-6; discussion 1606. PubMed ID: 16952698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The urological screening of children with myelodysplasia].
    Nikolaev VV; Braev AT
    Zh Vopr Neirokhir Im N N Burdenko; 2000; (1):27-9; discussion 29-30. PubMed ID: 10738762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What is the variability between 2 consecutive cystometries in the same child?
    Chin-Peuckert L; Komlos M; Rennick JE; Jednak R; Capolicchio JP; Salle JL
    J Urol; 2003 Oct; 170(4 Pt 2):1614-7. PubMed ID: 14501675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.